Funding

Since 2018 Creation of a technology platform for the diagnosis and therapy of mrsa - funded by the program: ProFit
This ProFIT project establishes an improved platform for producing camellia antibody fragments (VHH) for diagnostics and therapy. Using MRSA as a proof of concept, the project validates the "VHH immunojunction" technology in vivo and in vitro. Due to the pandemic, the scope has expanded to include therapeutic applications against SARS-CoV-2. The goal is to map the entire value chain—from R&D to commercialization (licensing, services, or products).
Funded by the European Regional Development Fund and the Federal State of Brandenburg.

Since 2024 STARLITE Project funded by Projektträger der BMWK - ZIM-Kooperationsprojekte
The STARLITE project focuses on engineering specialized single-domain antibody (sdAb) libraries to pinpoint binders for novel tumor targets. This research focuses on integrating these tumor-specific sdAbs into Stratosvir’s therapeutic virus construct to create an enhanced viral immunotherapy. By generating immune sdAb libraries against tumor and other human targets, the project seeks to provide licensed resources that facilitate the broader screening and development of therapeutic antibodies.

Since 2024 PHAROS Project funded by BMBF, Projektträger Jülich
The Pharos project strives to transform diagnostics by establishing a Point-of-Care alternative to complex clinical flow cytometry for evaluating cell surface markers. This research concentrates on adapting a specific intracellular mechanism—where fluorescent camelid antibody fragments undergo degradation by proteasomes only when unbound—into a functional extracellular, cell-free system. By employing this innovative "one-pot" assay with active cell lysates, the project endeavors to supersede expensive laboratory procedures, facilitating faster, decentralized, and cost-effective diagnosis of conditions such as leukemia and lymphoma.

Since 12/2025 Botulinum Neurotoxin A-Nukleinsäure-basierte Therapie BoNTANA, sponsored by ILB, ProFit
The BoNTANA project aims to develop two innovative pharmaceutical products that deliver the active ingredient Botulinum Neurotoxin A as a nucleic acid instead of the traditional protein form. This research focuses on creating an injectable formulation for treating movement disorders and a transdermal application for conditions such as hyperhidrosis and wrinkles. By utilizing this gene therapy approach with targeted expression in the neuromuscular junction, the project seeks to extend the duration of the effect, improve safety, and enable treatment for patients who have developed immunity to standard Botox proteins.
This project is funded by the European Regional Development Fund and the Federal State of Brandenburg.

Cooperations:

Dept. Chemical Life Sciences, University of Parma, ITALY www.unipr.it
Stiftungsprofessur Immuntechnologie, University of Potsdam, GERMANY
Medizinische Hochschule Hannover, GERMANY

For more information see:
www.bundeswirtschaftsministerium.de or www.ec.europa.eu